Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Diarrhea 1Breast Neoplasms 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Colesevelam Hydrochloride × Clear all
NCT03767257 2025-10-21

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
25 enrolled 6 charts
Plasma cell

Diarrhea, Multiple Myeloma

NCT02619812 2017-06-14

Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT

Mayo Clinic

Phase 2 Terminated
4 enrolled 4 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡